Article Abstract

CheckMate-032 Study: promising efficacy with nivolumab-based immunotherapy in pretreated esophagogastric cancer

Authors: Der Sheng Sun, Jae Jun Kim, Yoon Ho Ko


Esophagogastric junction (EGJ) cancer is one of the aggressive malignant tumors, and more than 60% of EGJ cancer patients develop recurrence or metastasis in the clinical course (1). Despite active frontline systemic chemotherapy, the prognosis of patients with recurrent or metastatic EGJ cancer is poor, and poor physical condition of the patient at the time of progression may render her/him inappropriate for active systemic cytotoxic chemotherapy (2).